BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $83 from $86 and keeps a Buy rating on the shares. The firm comes away from the “encouraging” Q1 updates with “few changes to the core thesis,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83
- CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
- Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)
- Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
- Cathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks